GIANT CELL ARTERITIS
Clinical trials for GIANT CELL ARTERITIS explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can tapering tocilizumab prevent relapse in giant cell arteritis?
Disease control OngoingThis study looks at the best way to stop tocilizumab in people with giant cell arteritis, a condition that causes inflamed blood vessels. About 120 participants will either stop the drug suddenly or taper it gradually. The goal is to see which approach lowers the chance of relaps…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 23, 2026 19:34 UTC
-
Cheaper drug could rival expensive biologic for rare artery disease
Disease control OngoingThis Phase 3 trial tests whether methotrexate, a common and affordable drug, works as well as the more expensive biologic tocilizumab for treating giant cell arteritis, a condition that causes inflamed arteries. About 230 adults will receive either methotrexate or tocilizumab for…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
New imaging methods could transform PMR diagnosis
Diagnosis OngoingThis study explores whether ultrasound and PET/CT scans can more accurately diagnose and monitor polymyalgia rheumatica (PMR), a condition causing muscle pain and inflammation. Researchers will follow 98 adults over 50 suspected of having PMR, using imaging at key points during t…
Matched conditions: GIANT CELL ARTERITIS
Sponsor: Kresten Krarup Keller • Aim: Diagnosis
Last updated Jun 11, 2026 12:11 UTC